Altimmune, Inc. - Common Stock (ALT)
6.6100
-0.0500 (-0.75%)
Altimmune Inc is a biotechnology company focused on developing novel therapeutics for the treatment of liver diseases, respiratory infections, and immune-mediated disorders
The company's innovative approach includes the development of immunotherapeutics and vaccine candidates that aim to harness the body’s immune system to combat various health conditions. Altimmune employs advanced scientific techniques to create therapies that can improve patient outcomes and address unmet medical needs in the healthcare landscape. Through its research and development efforts, the company seeks to bring forward transformative treatments that enhance quality of life and offer new solutions for patients facing significant health challenges.
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Via Benzinga · January 23, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/08/untitled.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 8, 2025
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.
Via Talk Markets · December 20, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/04/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/options_image_4.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 13, 2024
![](https://investorplace.com/wp-content/uploads/2022/07/alt-1600.jpg)
ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/12/Tyson-Foods--Inc--TSN---1-84-Of-Portfoli.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 12, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/12/Nvidia-Corporation-NVDA.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 12, 2024
![](https://www.marketbeat.com/images/MarketBeat-icon-256x256.png)
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
Via MarketBeat · November 9, 2024
![](https://www.marketbeat.com/logos/articles/med_20241107104136_how-altimmune-could-grab-a-big-chunk-of-the-glp-1.png)
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.
Via MarketBeat · November 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/11/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop)
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via Benzinga · October 11, 2024
![](https://g.foolcdn.com/editorial/images/790099/gettyimages-1295344478-1.jpg)
Telemedicine once seemed like it was going to revolutionize healthcare.
Via The Motley Fool · September 17, 2024
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
Via InvestorPlace · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2023/01/under10dollars1600-1024x576.png)
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.
Via InvestorPlace · August 11, 2024
![](https://g.foolcdn.com/editorial/images/785878/mergers-and-acquisitions-graphic-calculator-4.jpg)
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Via The Motley Fool · August 9, 2024
![](https://g.foolcdn.com/editorial/images/784833/gettyimages-1498947160.jpg)
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
Via The Motley Fool · August 2, 2024
![](https://g.foolcdn.com/editorial/images/783710/researchers-work-in-the-lab.jpg)
At least one of the pair has a credible shot at finding a home in the market.
Via The Motley Fool · July 20, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements
Via InvestorPlace · July 19, 2024
![](https://investorplace.com/wp-content/uploads/2024/05/timemoney1600.jpg)
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.
Via InvestorPlace · July 17, 2024
![](https://g.foolcdn.com/editorial/images/781835/scientists-confer-in-lab.jpg)
Both competitors have promising lead programs, and enough cash, too.
Via The Motley Fool · July 10, 2024
![](https://investorplace.com/wp-content/uploads/2019/05/stock-picks.jpg)
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
Via InvestorPlace · July 9, 2024
![](https://investorplace.com/wp-content/uploads/2019/07/cheapstocks1600.jpg)
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
Via InvestorPlace · July 6, 2024
![](https://g.foolcdn.com/editorial/images/781808/scientists-confer-at-lab-bench.jpg)
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
Via The Motley Fool · June 30, 2024